Lichenoid drug eruption after treatment with ixekizumab for plaque psoriasis

Neda Ghiam, Oben Ojong, Gabriella Vasile, Paolo Romanelli, Francisco Kerdel

Research output: Contribution to journalArticlepeer-review


Lichen planus, the prototype of lichenoid dermatoses, is an idiopathic, T cell-mediated, autoimmune, inflammatory disease. It may affect the skin, hair, nails, and mucous membranes. Many clinical variants of lichen planus have been described, including lichenoid drug eruption or drug induced lichen planus, associated with a myriad of culprit medications. We describe a 63-year-old woman with longstanding psoriasis effectively controlled with ixekizumab, who developed lichenoid drug eruption. Her lichen planus lesions improved after treatment discontinuation and the patient was started on an IL23 inhibitor to treat her psoriasis through an alternative mechanism of action. Our report adds to the literature and provides insight into the complex pathophysiology of lichen planus.

Original languageEnglish (US)
JournalDermatology online journal
Issue number12
StatePublished - Dec 2020


  • Ixekizumab
  • Lichen planus
  • Psoriasis

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Lichenoid drug eruption after treatment with ixekizumab for plaque psoriasis'. Together they form a unique fingerprint.

Cite this